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methylation density using a microparticle-based flow cytometry assay†
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DOI: 10.1039/c0an00790kDNA methylation analysis is emerging as a new technique with
potential capabilities for early cancer detection. However, current
state-of-the-art techniques are not easily translatable into routine
clinical methods. Herein we describe a bead-based flow cytometry
assay which combines DNA hybridization to microparticles with
5MeC-specific proteins/antibodies. These assays can be used to
study the binding properties of current and emerging 5MeC-binding
proteins and may also have potential in the measurement of 5MeC
density in clinical samples for cancer detection.Fig. 1 Bisulfite conversion chemically converts unmethylated cytosine
bases (clear circles) to uracils without affecting 5MeC bases (filled circles)
(A), however, this is a time-consuming process which results in significant
DNA degradation. Methylation-specific PCR involves amplifying bisul-
fite-converted DNA in the presence of primers which are designed to onlyEpigenetic regulation of gene expression plays a critical role in
developing and maintaining eukaryotic cells and organisms.1,2
Aberrant changes in 5-methylcytosine (5MeC) density in gene
promoters (‘‘CpG islands’’) are correlated with oncogenesis in
a range of both solid organ and hematopoietic cancers.3,4 Both
hypermethylation in gene-specific CpG islands and hypomethylation
in repetitive sequences (ALU, LINE-1, etc.) have been used to
distinguish cancers from healthy tissue, sometimes at the early
stage.5,6
The technology most commonly employed to quantify the location
and density of 5MeC is a combination of bisulfite conversion
(chemical conversion of unmethylated C/ U bases whilst leaving
5MeC unmodified) with sequencing. This method, referred to as
‘‘Bisulfite Sequencing’’ (BS), is capable of distinguishing C/U differ-
ences at single-base resolution.7 Coupled with ‘‘Next-Gen’’
sequencing technologies, the capability for genome-wide methylation
mapping will continue to improve.7 However, bisulfite techniques
may be too complicated and costly (8–18 h pre-PCR8) for routine
clinical use in the near future. Initially, diagnostic tests using
methylation analysis are likely to focus on quantifying the relative
concentration of 5MeC in a well-characterized DNA sequence9 (or
sequences), for which the extra time and cost of single-base resolution
methods are unjustified.
PCR methods have been developed based on the amplification of
bisulfite-converted DNA in the presence of methylation-specific
primers. Both endpoint assays (methylation-specific PCR or MSP)
and real-time (MethyLight) assays have been developed based on this
concept, however, they show poor agreement and significant vari-
ability when compared to BS.10 Problems include those associated
with bisulfite conversion (time, cost, sample degradation) and theaThe University of Queensland, Australian Institute for Bioengineering and
Nanotechnology, Centre for Biomarker Research and Development, St
Lucia, Brisbane, Australia. E-mail: m.trau@uq.edu.au; Fax: +61 7 3346
3973; Tel: +61 7 3346 4173
bUniversity of Washington, School of Medicine, Department of Pathology,
Seattle, USA
† Electronic supplementary information (ESI) available: Experimental
methods. See DOI: 10.1039/c0an00790k
688 | Analyst, 2011, 136, 688–691limitation of having to design PCR amplicons around 5MeC-rich
primers without dependence on the 5MeC density in-between.
Another class of methylation assays involves selective recognition
of 5MeC by anti-5MeC-antibodies (MeDIP—methylated DNA
immunoprecipitation) or proteins containing 5MeC-binding domains
(MIRA—methylated-CpG island recovery assay). Neither method
requires bisulfite, rather a DNA sample is separated into methylated
and unmethylated fractions by resin-bound proteins, after which
standard PCR analysis can be used to estimate methylation density in
specific loci. While NMR studies have been used to investigate the
binding mechanisms of some 5MeC-binding proteins (MBPs) to
symmetrically methylated dsDNA,11 there is still much to learn about
these interactions. An assay which can rapidly analyse the binding
characteristics of MBPs as a function of DNA sequence and structure
may be extremely useful in identifying the most appropriate MBP for
specific applications.
Herein we report a method for measuring the 5MeC density of
a DNA sequence without the need for bisulfite conversion. In its
simplest form, we believe it is useful for rapidly screening MBPs to
determine DNA sequence/structure-dependent binding affinities.
However, there is also the potential for this simple assay to be used in
cancer screening strategies to quantify the relative 5MeC density in
gene-specific or repetitive loci.amplify sequences containing unconverted 5MeC. However, this places
further restrictions on the design of PCR primers and probes, and is only
sensitive to 5MeC bases contained within the primer/probe sequences
themselves. By combining a microparticle assay with affinity recognition
of the 5MeC base (B), we are able to selectively extract DNA loci of
interest from a sample, then measure the 5MeC density of the sequence by
incubation with MBPs and FITC-labelled secondary antibodies. Relative
quantitation of the fluorescent signals is performed rapidly and robustly
using flow cytometry.
This journal is ª The Royal Society of Chemistry 2011
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View Article OnlineAn assay using a combination of DNA hybridization and protein
recognition was developed to replace bisulfite conversion for locus-
specific methylation analysis (Fig. 1). DNA sequences of interest were
isolated from the solution by locus-specific hybridization to probe-
functionalized microparticles (for detailed characterization of the
organosilica microparticles employed in this study, the reader is
directed to a range of publications from our group12–16). Subsequent
incubation with MBPs and FITC-labelled antibodies yielded fluo-
rescent signals indicative of the 5MeC content. Importantly, by
incorporating a PEG (polyethylene glycol) linker into the silica
microparticles and using a low surfactant concentration in the
protein/antibody incubation steps (0.1% Tween-20), we were able to
minimise non-specific binding between the MBPs or antibodies and
the microparticles. We chose to investigate two different MBPs.
GST-MBD2b (Fig. S1†) has previously been reported to bind
double-stranded DNA (dsDNA) specifically,17 while the 5MeC-Ab
reportedly binds only to single-stranded sequences (ssDNA).18 Flow
cytometry was used to score the fluorescence intensity of thousands
of individual microparticles in each sample to provide a semi-quan-
titative measure19 of DNA methylation. We show that the assay can
be used to assess and compare binding properties of MBPs using
model DNA substrates, identifying previously unknown single-base
resolution binding to hemi-methylated DNA. Furthermore, we were
able to detect hypomethylation of ALU and LINE-1 sequences in
only 10 mL of serum extracted from women with invasive breast
cancer in comparison to healthy controls.
Binding of MBPs to symmetrically methylated probe/target
combinations yielded results similar to those from a previous study
investigating a similar MBP20 (Fig. S2†) and identical probe/target
sequences (Table S1†). However, we hypothesised that MBPs may
also bind hemi-methylated DNA, in which only the target sequence
contains the 5MeC bases of interest. This would represent a signifi-
cant advantage for a diagnostic assay as the target 5MeC density
could be measured using a completely unmethylated probe sequence.
Fig. 2A shows that the GST-MBD2b protein could bind aFig. 2 Hemi-methylated DNA analysis by microparticle assay; (A)
linear response curves generated from hemi-methylated DNA using
DOM-0-NH2 probe-functionalised microparticles and targets of
increasing 5MeC density or (B) linear response curves generated from
hemi-methylated DNA using DOM-12-NH2 probe-functionalised
microparticles and targets of increasing 5MeC density; (C) schematic of
GST-MBD2b binding footprints as indicated by results from (A) and (B).
This journal is ª The Royal Society of Chemistry 2011hemi-methylated substrate containing only a single 5MeC, and that
increasing the 5MeC density of the target sequence resulted in a linear
increase in MBP binding (p-value < 0.0001). Replacing the unme-
thylated probe (DOM-0-NH2) with the fully methylated sequence
(DOM-12-NH2) resulted in a similar linear trend (Fig. 2B) but with
a significantly higher y-intercept, suggesting that individual changes
in the target methylation density were detectable regardless of probe
methylation density. From these results we were able to infer an
approximate ‘‘footprint’’ of the protein on the DNA (Fig. 2C), sug-
gesting on average single-base resolution up to at least 12 5MeC bases
in the target strand. As expected, the 5MeC-Ab showed low binding
to the dsDNA substrates (Fig. 2B) in accordance with previous
observations, however, a linear trend was present (p-value ¼ 0.0013
for both) with 3 methylated bases required for minimum signal
detection.
We next investigated MBP binding to microparticle-bound
duplexes containing a ssDNA target ‘‘overhang’’ (Fig. 3). We
hypothesised that this may result in favourable conditions for 5MeC-
Ab binding, based on previous studies reporting a preference for
ssDNA targets. Furthermore, assays involving short probes and long
targets are more common for DNA hybridization applications, thus
it was important to identify which MBP performed best under these
conditions. Keeping the total target concentration constant, we
mixed the unmethylated and methylated long target sequences (70nt)
together in different ratios to make a dilution series. We then incu-
bated these target samples with short (40nt) or long (70nt) probes
bound to microparticles and exposed them to the MBPs (Fig. 3).
Fig. 3A shows that both MBPs have very similar binding affinities to
the samples when a target overhang is present, while the 5MeC-Ab
could detect a lower percentage of methylated DNA in comparison
to the GST-MBD2b (10% vs. 25%). Fig. 3B shows that the 5MeC-Ab
had significantly lower affinity for the substrate containing probe and
target of the same length, a result similar to that in Fig. 2.
To investigate the utility of our assay in real clinical samples, we
measured ALU and LINE-1 methylation using the 5MeC-Ab, in
a small cohort of human serum samples extracted from women with
or without invasive breast cancer. We used the 5MeC-Ab instead of
the GST-MBD2b because of the lower detection limit (Fig. 3A) and
also due to the ALU/LINE-1 assay design involving long ssDA
overhang sequences. Hypomethylation of ALU and LINE-1 repeti-
tive elements is a known hallmark of cancer and has been identified in
the serum and tissue of many cancers including breast.6,21–24 TheFig. 3 ssDNA target overhang analysis by microparticle assay; (A)
hybridization of short probes with long targets thus producing a target
‘‘overhang’’; (B) hybridization of long probes with long targets,
producing a duplex of equal length. Note that MBP-specific fluorescence
intensity is presented here after normalisation based on the hybridized
DNA amount, which varied predictably based on the probe length
(Fig. S3†).
Analyst, 2011, 136, 688–691 | 689
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View Article Onlinehistological diagnosis of the samples was confirmed by a pathologist
(NBK) and presented in a separate study.5
In order to maximize the hybridization efficiency25 we designed
three probes each (30 bp) for both the human ALU consensus
sequence and the human LINE-1 sequence (both >200nt26,27), and
attached these in a mixture to microparticle batches (Table S1†). As
a negative control, we included in the testing panel particles without
any conjugated probes, which yielded FITC signals at background
levels. Hybridization reactions were performed using only 10 mL
serum DNA, the concentration of which were undetectable by
nanodrop (i.e. <1 ng mL1). Therefore we used qPCR to measure the
concentration of ALU/LINE-1 in the patient samples (Table S2†) in
order to normalize the methylation data for direct comparisons. The
normalised methylation data for the clinical samples (‘‘methylation
scores’’) are presented in Fig. 4. Methylation of both LINE-1 and
ALU sequences was significantly higher in serum from normal
controls than serum from breast cancer patients (p-values < 0.05
using Mann Whitney test), consistent with previous observations in
similar studies investigating hypomethylation of repetitive elements in
breast cancer.21–23 Overall, LINE-1 methylation scores were higher
than those for ALU regardless of normal or cancer samples, indic-
ative of higher methylation density in LINE-1 sequences which is
consistent with other studies investigating hypomethylation in
a range of human cancers.
The microparticle assay presented in this study revealed significant
MBP binding to hemi-methylated DNA. Furthermore, the binding
footprint of the GST-MBD2b protein is apparently much larger in
the case of symmetric DNA methylation when compared to the
hemi-methylated case. This could be explained by only one of the two
potential binding sites11 being occupied in the latter case, such that
less of the protein is interacting with the DNA. Along with evidence
of 5MeC-Ab binding to dsDNA, this contradicts previously sug-
gested binding preferences for these MBPs. These assays may
therefore prove useful in screening MBPs in a high-throughput
manner, changing the composition of the DNA target (ssDNA,
dsDNA, symmetric versus hemi-methylation, etc.).
Several elements of the current prototype need further improve-
ment for clinical application. Future work will focus on testing more
clinical samples and improving the sensitivity of the method for
clinical application. Firstly, whilst hypomethylation of repetitive
sequences may be of interest as a general cancer biomarker,Fig. 4 ALU and LINE-1 microparticle-based methylation scores for
serum extracted from women with and without invasive breast cancer
using 5MeC-antibody as the detection agent. Note that box indicates
interquartile range (25th to 75th percentile) and whiskers indicate max/min
values.
690 | Analyst, 2011, 136, 688–691hypermethylation of single-copy sequences in promoters/CpG-
islands is tissue and cancer-specific. However, the sensitivity of the
assay with respect to the number of target molecules hybridized per
microparticle is limiting at this stage. For example, a typical locus is
present at 1 copy per 3.3 pg of DNA, therefore 100 ng will contain
30 000 copies of each locus. The hybridization efficiency of reac-
tions involving PCR products may be as low as 1–10%, leaving only
300–3000 copies hybridized to the microparticles. If 1000 micropar-
ticles are used for the reaction and subsequent flow cytometry, there
may be as low as 3–30 targets bound to each microparticle. The
nominal sensitivity limit for the BDLSR2 flow cytometer is only40
molecules of FITC (BD Biosciences). This explains why repetitive
sequences are easier to analyse—ALU and LINE-1 sequences are
present at0.5 to 1 106 copies per genome.6 However, advances in
hybridization assay optimization (e.g.minimizing surface density, use
of non-native DNA probes to increase Ka, MBPs of increased
affinity, etc.) will be investigated in developing the next generation
assays. Secondly, incorporation of an internal control measurement
for particle-bound DNA would reduce the need for methods such as
qPCR or nanodrop analysis. Finally, a key advantage inherent to
microparticle technologies is the ease of multiplexing using optically
distinguishable beads,15,16 which will be investigated in future gener-
ations of the assay in order to measure the 5MeC density of multiple
loci in the same test, which should work to reduce false positives and
improve clinical specificity.
We have reported the development of a DNA methylation assay
which can quantify the methylation density of a specific DNA locus
without the need for bisulfite conversion. Using model systems con-
sisting of a dsDNA duplex containing hemi-methylated CpG-dinu-
cleotides, we identified that both MBPs under investigation could
bind to hemi-methylated DNA. We suggest this assay may be of
interest in the development of high-throughput cancer detection
assays based on ALU/LINE-1 methylation and also in the develop-
ment of research techniques focusing on quantitative analysis of the
binding characteristics of MBPs.
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